Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study

Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis

(2016) Jianmei Wang et al.   ARTHRITIS CARE & RESEARCH

The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study

(2015) Andres J Yarur et al.   GUT

Monoclonal antibodies in excess: A simple way to avoid immunogenicity in patients?

(2015) Benjamin Chaigne et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients

(2015) Karien Bloem et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis

(2015) Stef P. Menting et al.   JAMA Dermatology

Key findings towards optimising adalimumab treatment: the concentration–effect curve

(2013) Mieke F Pouw et al.   ANNALS OF THE RHEUMATIC DISEASES

Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy

(2013) Naoshi Nishina et al.   ANNALS OF THE RHEUMATIC DISEASES

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease

(2013) Jean–Frédéric Colombel et al.   Clinical Gastroenterology and Hepatology

Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study)

(2013) Shuji Ohta et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice

(2013) Yves-Marie Pers et al.   RHEUMATOLOGY

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis

(2013) Atsushi Ogata et al.   ARTHRITIS CARE & RESEARCH

IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis

(2013) Jianmei Wang et al.   BMJ Open

Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions

(2013) Jose Ramon Maneiro et al.   JAMA Internal Medicine

IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6

(2012) Stefan Rose-John   International Journal of Biological Sciences

Exposure-Exposure Relationship of Tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis

(2012) Micha Levi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody

(2011) Theo Rispens et al.   ANALYTICAL BIOCHEMISTRY

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Differential effect of drug interference in immunogenicity assays

(2011) Margreet H. Hart et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing

(2011) Theo Rispens et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI

(2011) Atsushi Kaneko et al.   RHEUMATOLOGY INTERNATIONAL

Dealing with immunogenicity of biologicals: assessment and clinical relevance

(2010) Gerrit J Wolbink et al.   CURRENT OPINION IN RHEUMATOLOGY

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

(2010) Shigeru Kotake et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis

(2010) Nicolas Frey et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients

(2010) Pauline A. van Schouwenburg et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

IL-6R distribution in normal human and cynomolgus monkey tissues

(2008) Atsuhiko Kato et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY